Comparative Pharmacology
Head-to-head clinical analysis: FLUDEOXYGLUCOSE F18 versus SELENOMETHIONINE SE 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDEOXYGLUCOSE F18 versus SELENOMETHIONINE SE 75.
FLUDEOXYGLUCOSE F18 vs SELENOMETHIONINE SE 75
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fludeoxyglucose F18 is a glucose analog that is taken up by cells via glucose transporters (GLUT), particularly GLUT-1. It is phosphorylated to FDG-6-phosphate by hexokinase, which cannot be further metabolized, leading to intracellular accumulation proportional to glucose metabolism. It emits positrons detected by PET imaging.
Radiopharmaceutical agent: selenium-75 decays by electron capture to arsenic-75 with emission of gamma photons. Used as a tracer for pancreatic imaging due to incorporation into pancreatic enzymes. Localizes in pancreas via protein synthesis.
5-10 mCi (185-370 MBq) intravenous injection, single dose for PET imaging.
0.185-0.37 MBq (5-10 μCi) intravenously as a single dose for pancreatic imaging.
None Documented
None Documented
Terminal elimination half-life is approximately 110 minutes (range 100–120 minutes). This reflects clearance of unmetabolized FDG from plasma and is clinically relevant for imaging timing, as optimal image acquisition occurs 30–60 minutes post-injection to allow for target-to-background ratio maximization.
Terminal half-life is approximately 50-60 days, reflecting slow turnover of selenomethionine incorporated into body proteins (e.g., skeletal muscle, erythrocytes).
Primarily renal; approximately 90% of injected activity is excreted unchanged in urine within the first 2 hours post-injection. Less than 5% is eliminated via feces.
Primarily renal, with 20-30% excreted unchanged in urine; minor fecal elimination (<5%). The remainder is incorporated into endogenous proteins and long-term tissue stores.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical